Advances on the relationship between thrombin-activatable fibrinolysis inhibitor (TAFI) and recurrent pregnancy loss

doi:10.11958/j.issn.0253-9896.2015.03.028

Abstract

Abstract: Recurrent pregnancy loss (RPL) is a common complication of pregnancy, which affects 2% fertile women. A recent research has found that high level of thrombin-activatable fibrinolysis inhibitor (TAFI) can reduce the occurrence risk of early RPL. TAFI is one kind of carboxypeptidase, which can be activated as TAFIa. TAFIa can make the fibrinolysin lose its working site, which can interact with the fibrin to play a role in the regulation of fibrinolysis and the inhibition of throm⁃ bus formation. The damage of fibrinolytic system is one of the risk factors for the occurrence of RPL in pregnant women, which has become one of the hotspots in the medical profession. In this paper, recent literature on TAFI and its relationship with recurrent pregnancy loss has been reviewed, hoping for new ways and clues in clinical treatment and prevention of RPL.

Key words: thrombin, plasminogen inactivators, abortion, habitual, review, thrombin-activatable fibrinolysis inhibitor

References

1. Marx PF, Brondijk THC, Plug T, et al. Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI: a novel mechanism for enzyme autoregulation[J]. Blood, 2008, 112: 2803–2809. 2. Vercauteren E, Emmerechts J, Peeters M, et al. Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism model[J]. Blood, 2011, 117: 4615–4622. 3. Mishra N, Vercauteren E, Develter J, et al. Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms[J]. J. Thromb Haemost, 2011, 106(1):90-101. 4. Marx PF, Plug T, Havik SR, et al. The activation peptide of thrombin-activatable fibrinolysis inhibitor: a role in activity and stability of the enzyme? J. Thromb Haemost, 2009, 7(3):445-452. 5. Hillmayer K, Vancraenenbroeck R, Maeyer DM, et al. Discovery of novel mechanisms and molecular targets for the inhibition of activated thrombin activatable fibrinolysis inhibitor[J]. J.Thromb Haemost, 2008, 6(11): 1892–1899. 6. Buelens K, Hassanzadeh G, Muyldermans S, et al. Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor[J]. J.Thromb Haemost, 2010,8(6): 1302–1312. 7. Mosnier LO, Buijtenhuijs P, Marx PF, et al. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets[J]. Blood, 2003, 101(12): 4844–4846. 8. Gils A, Alessi MC, Brouwers E, et al. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol, 2003, 23(6): 1122–1127. 9. Boffa MB, Maret D, Hamill JD, et al. Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis[J]. Blood,2008,111(1): 183–189. 10. Watanabe T, Minakami H, Sakata Y, et al. Changes in activity of plasma thrombin activatable fibrinolysis inhibitor in pregnancy [J]. Gynecol Obstet Invest , 2004 , 58( 1 ): 19-21. 11. Declerk PJ. Thrombin activatable fibrinolysis inhibitor[J]. Hamostaseologie, 2011, 31(3):165–173. 12.王丽丽,徐成伟. 凝血酶激活的纤溶抑制物TAFI的研究进展[J]. 血栓与止血学,2007,13(1):41-44. 13. Walker JB, Bajzar L. The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability[J]. J Biol Chem, 2004, 279(27): 27896–27904. 14. Leurs J, Nerme V, Sim Y, et al. Carboxypeptidase U (TAFIa) preventslysis from proceeding into the propagation phase through a threshold-dependent mechanism[J]. J Thromb Haemost, 2004,2(3): 416–423. 15. Heylen E, Willemse J, Hendriks D. An update on the role of carboxypeptidase U (TAFIa) in fibrinolysis[J]. Front Biosci, 2011,1(16): 2427–2450. 16. Folkeringa N, Korteweg FJ, Veeger NJ, et al. Thrombin activatable ?brinolysis inhibitor (TAFI) is not associated with fetal loss, a retrospective study[J]. Thromb Res,2009,123(3): 511–514. 17.Knol HM, Veeger NJ, Middeldorp S, et al. High thrombin-activatable ?brinolysis inhibitor levels may protect against recurrent fetal loss[J]. Thromb Haemost . 2009, 7(5): 903–906. 18. Masini S, Ticconi C, Gravina P, et al. Thrombin-activatable ?brinolysis inhibitor polymorphisms and recurrent pregnancy loss[J]. Fertil Steril, 2009,92(2):694-702. 19. Pruner I, Djordjevic V, Miljic P, et al. +1040C/T polymorphism in coding region of thrombin-activatable fibrinolysis inhibitorgene and the risk of idiopathic recurrent fetal loss[J]. Blood Coagul Fibrinolysis,2010,21(7):679–682. 20. Martinez-Zamora MA, Creus M, Tassies D, et al. Thrombin activatable fibrinolysis inhibitor and clot lysis time in women with recurrent miscarriage associated with the antiphospholipid syndrome[J].Fertil Steril, 2010,94(6):2437–2440. 21. Legnani C, Bovara M, Valdre L, et al. Risk of early recurrent fetal loss and levels of thrombin-activatable ?brinolysis inhibitor[J]. Thromb Res,2011,130(2):237-241. 22. Guo YH, Hernandez I, Isermann B, et al. Caveolin-1-dependent apoptosis induced by ?brin degradation products[J].Blood, 2009,113(18):4431–4439. 23. Kwak-Kim J, Yang KM, Gilman-Sachs A. Recurrent pregnancy loss: A disease of in?ammation and coagulation. J Obstet Gynaecol Res 2009;35(4):609–622. 24. Marx, Pauline F, Chantal J, et al. Recent developments in thrombin-activatable fibrinolysis inhibitor research[J]. Mini Reviews in Medicinal Chemistry,2009, 9(10):1165-1173.

[1]	LIU Zhichao, LI Xiaohe, ZHOU Honggang, ZHANG Na. Overview of animal models of idiopathic inflammatory myopathy-associated interstitial lung disease [J]. Tianjin Medical Journal, 2024, 52(7): 709-713.
[2]	ZHANG Shijie, MENG Xianchun, SUN Pingping, YANG Jingjing, WU Jing. The value of new coagulation markers in the diagnosis and prognosis evaluation of neonatal disseminated intravascular coagulation [J]. Tianjin Medical Journal, 2024, 52(2): 206-209.
[3]	XIE Yunfan, LIU Mi, TIAN Yi. Research progress on effects of sevoflurane on apoptosis related signal pathways of hippocampal neurons [J]. Tianjin Medical Journal, 2022, 50(8): 892-896.
[4]	LU Songsong, LI Meng, NURZAT·Huerman , DING Qingming, XU Qinzhu, SONG Ying, SU Ming. Evaluation of the effect of activated carbon on reversing the interference of rivaroxaban on coagulation experiment [J]. Tianjin Medical Journal, 2022, 50(12): 1287-1291.
[5]	LIU Jie, XIA Pan, PAN Chunhua, LI Hang, WANG Zeying. Research progress on early neurological deterioration after vascular recanalization in acute ischemic stroke [J]. Tianjin Medical Journal, 2022, 50(11): 1227-1232.
[6]	LI Dan, GAO Shan. Research progress on the role of NLRP3 inflammasome in myocardial ischemia-reperfusion injury #br# [J]. Tianjin Medical Journal, 2021, 49(6): 656-662.
[7]	ZHAO Yu, ZHANG Jun-ling, FENG Guo-xing, FAN Sai-jun△. Research progress on the role of STAT5 in tumors [J]. Tianjin Medical Journal, 2020, 48(7): 670-676.
[8]	ZHANG Xiao-fei, LYU Zhen, WANG Xiao-quan, LIU Jun△. The mechanism of aseptic loosening around artificial joint prostheses #br# [J]. Tianjin Medical Journal, 2020, 48(6): 572-576.
[9]	ZHI Xiang-cheng, CAO Li-xia, SHI Zhen-dong, LIU Jing-jing, ZHANG Jin△. Research progression in the treatment of breast tumors with Chidamide #br# [J]. Tianjin Medical Journal, 2020, 48(6): 567-571.
[10]	LI Pu, DU Xiao-qin. Research progress of miR-27a in gynecological tumors [J]. Tianjin Medical Journal, 2020, 48(5): 455-459.
[11]	HUO Xing-yu, GENG Jie△. Progress in the relationship between intestinal flora and its metabolites with cardiovascular diseases #br# [J]. Tianjin Medical Journal, 2020, 48(5): 460-464.
[12]	ZHUANG Xin-qi, XIE Ke-liang, YU Yong-hao, LU Yue-chun, LYU Guo-yi. Advances in research on microglia and sepsis associated encephalopathy #br# [J]. Tianjin Medical Journal, 2020, 48(4): 338-342.
[13]	SUN Yu-fu, YAN Jun. Research progress on the mechanism of skeletal muscle ischemia-reperfusion injury affected by hydrogen sulfide [J]. Tianjin Medical Journal, 2020, 48(2): 152-155.
[14]	LI Xiao, ZHOU Shuang, ZHAO Chen. Research progress on the molecular biological mechanism of long non-coding RNA regulating angiogenesis after ischemic stroke [J]. Tianjin Medical Journal, 2020, 48(12): 1236-1239.
[15]	ZOU Yun-lei, LIU Xiao-hui, HU Bing, LIU Zhao-qi, ZHAO Yun△. Application of ultrasound targeted microbubble destruction in gene therapy of myocardial infarction [J]. Tianjin Medical Journal, 2020, 48(11): 1131-1136.